Menu
Search
|

Menu

Close
X

Verastem Inc VSTM.OQ (NASDAQ Stock Exchange Global Market)

1.34 USD
+0.03 (+2.29%)
As of Sep 13
Previous Close 1.31
Open 1.32
Volume 136,590
3m Avg Volume 368,861
Today’s High 1.37
Today’s Low 1.32
52 Week High 9.31
52 Week Low 1.16
Shares Outstanding (mil) 73.88
Market Capitalization (mil) 105.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
2
FY18
27
FY17
0
FY16
0
EPS (USD)
FY19
-0.516
FY18
-1.162
FY17
-1.763
FY16
-0.985
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
3.72
7.90
Price to Book (MRQ)
vs sector
1.19
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
137.88
17.64
LT Debt to Equity (MRQ)
vs sector
137.88
12.61
Return on Investment (TTM)
vs sector
-66.70
12.69
Return on Equity (TTM)
vs sector
-140.91
17.13

EXECUTIVE LEADERSHIP

Daniel Paterson
President, Chief Operating Officer, Since 2019
Salary: $363,058.00
Bonus: --
Robert Gagnon
Chief Financial Officer, Chief Business Officer, Since 2019
Salary: $115,462.00
Bonus: $40,000.00
Steven Bloom
Chief Strategy Officer, Since 2017
Salary: --
Bonus: --
Joseph Lobacki
Chief Commercial Officer, Since 2018
Salary: $381,539.00
Bonus: $60,000.00
Michael Kauffman
Lead Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

117 Kendrick St Ste 500
NEEDHAM   MA   02494-2730

Phone: +1781.2924200

Verastem, Inc., is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. It is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma.

SPONSORED STORIES